Inspired by the broad and efficient application prospects of CD19‐targeted therapeutics in autoimmunity diseases, we developed mRNab‐LNPs targeting CD19 for the depletion of B cells and plasma cells and explored their efficacy in MRL/lpr lupus mice and CIA mice models. This evidence concerns the gene CD19 and autoimmune disease.